Dihexa Peptide: Benefits, side effects, dosage details, and how it works

A couple of factors could be driving recent interest in a peptide called dihexa. One is that it’s among the 12 peptides scheduled for FDA review in 2026 and 2027, which could lead to its reinstatement on the bulk compounding list and broader availability as a therapeutic treatment.1 The other may be the apparent increasing rates of cognitive disability among U.S. adults, which a drug like dihexa has the potential to attenuate.2

Over the past two decades, Innerbody Research has helped tens of millions of readers make more informed decisions about staying healthy and living healthier lifestyles.

With our more than 1,000 cumulative research hours on peptides, not to mention the untold time we’ve devoted to monitoring the peptide space, people have come to depend on our work to familiarize themselves with emerging therapies. We strive to make each piece on the subject both comprehensive and economical, complete yet approachable, so that readers come away with a fully functional understanding that helps guide their health decisions. Whenever possible, we also integrate knowledge from medical practitioners and peptide users, enabling us to provide practical, ground-level insights.

Additionally, like all health-related content on this website, this guide was thoroughly vetted by one or more members of our Medical Review Board for accuracy and will continue to be monitored for updates by our editorial team.

Dihexa is derived from the hormone angiotensin IV (Ang IV), which facilitates memory retention and retrieval.3 It is therefore an Ang IV analog, or a compound that structurally resembles Ang IV but with a componental difference. The key difference here is that dihexa is metabolically stable and capable of permeating the blood–brain barrier, whereas Ang IV is not.4 In other words, you can’t inject Ang IV directly and see any benefit, but you can with dihexa.

Dihexa’s origins trace back to the early 1990s, though it wasn’t successfully synthesized until 2012. It was originally intended as an Alzheimer’s treatment, but one that attacked the disease from a different approach. What distinguishes it from other Alzheimer’s treatments is that it’s designed to repair extant brain damage, rather than slow impending neuronal cell death. Its mechanism of action is corrective instead of preventive. Likewise distinguishing is its potential route of administration: capable of moving from the gut into the bloodstream, dihexa is bioavailable in pill form, as well as by injection.5 Relatively few peptide treatments are orally active.

Currently, dihexa’s only known therapeutic use is as a neuro-corrective agent. It’s designed to improve measures of cognitive performance. But neuro-correction is a big one, as far as therapeutic unitasking goes, and the research so far has been mostly positive.

In a systematic review, for example — one of the earliest reviews involving dihexa, in fact — the authors had this to say about the peptide:4

• “In models of cognitive deficit, eight of nine studies found Ang IV and its analogs (Nle1-Ang IV, dihexa, LVV-hemorphin-7) improved performance on spatial working memory and passive avoidance tasks.”
• “[Among Ang IV analogs,] Dihexa may be the most promising compound for testing in humans.”

Later reviews echo the 2018 findings and dig further into how dihexa works. Most recently, for example, a 2026 publication in the Journal of the American Academy of Orthopaedic Surgeons notes that in preclinical Alzheimer’s models, dihexa has led to the “restoration of memory function” and “enhanced synaptic connectivity” by potentiating or stimulating mechanisms associated with the formation of synapses and the refinement of neuronal connections.6

A critical shortcoming with the existing research on dihexa is that it has been conducted exclusively in animal models, and animal research doesn’t always translate to human efficacy. Thus, there’s a tight limit on what can be said about dihexa’s utility towards its neuro-corrective end.

The lack of human studies has left a similar gap in dihexa’s safety profile. Even with animal models to lean on, dihexa doesn’t have enough research behind it to support its long-term use.

The little that we know about dihexa’s safety actually raises a concern about its carcinogenic potential.

Dihexa’s mechanism of action involves binding to a protein called hepatocyte growth factor (HGF) and promoting signaling from HGF’s receptor, c-Met.5 It’s the same signaling pathway implicated in brain tumors and other cancers.7 8 9

This is all theoretical, to be sure. Again, there are no long-term safety studies, and therefore nothing to confirm or disconfirm the cancer risk. But it’s something to keep squarely on your mind should you want to try dihexa on your own.

Research-grade vs. pharmaceutical-grade dihexa

Every therapeutic peptide comes in one of two forms:

• Research-grade: intended for use in laboratories, and not in humans; no prescription needed
• Pharmaceutical-grade: a.k.a. medical-grade, suitable for human consumption; prescription required

The delineating factor between the two grades is purity.

The purity standards for research-grade peptides aren’t all that high. After all, they’re meant to be used in cell cultures or animal models, where the preservation of life isn’t always a concern. So a research-grade peptide might have a purity level as low as 60%, and it’s no big deal in a research setting.10

But if you start using low-purity substances in human subjects, that’s when things get dangerous. The high level of impurities increases the risk of immunogenicity, where the immune system reads the substance as a threat, the same as it would an allergen. In response, the immune system mounts a response (again, as it would to an allergen), which can in turn produce life-threatening adverse effects.11

As for pharmaceutical-grade drugs, you’re looking at purity levels of at least 99%. Against a research-grade counterpart, that’s like water from a filtered tap compared to rainwater on your car’s windshield: you’d be much safer consuming the former, and irresponsible to use the latter.

Lacking human studies, dihexa is one of those on-the-grapevine peptides without a standard treatment protocol. It isn’t even included in the more extensive peptide catalogs we’ve seen among our preferred telehealth providers. The use experience, then, is a matter of surmise based on the handful of animal studies currently in the literature. Keeping in mind that animal studies don’t necessarily equate to human use, you might expect the treatment protocol to look something like this:

Because research evidence suggests that dihexa’s function is corrective, not preventive, the ideal candidate for the peptide would be someone who is already showing signs of cognitive impairment. For example:14

• Frequent forgetting
• Losing one’s train of thought
• Difficulty with decision-making
• Difficulty finding the right word or following a conversation
• Getting lost or confused in familiar places
• Having a diagnosis involving cognitive impairment

That isn’t to say that dihexa can restore an impaired mind to its more vibrant, youthful state. Dihexa may have been developed as an Alzheimer’s treatment, but it’s unlikely to have such a revolutionary effect against neurodegeneration. Rather, dihexa may temporarily rejuvenate one’s cognitive faculties so that memories become easier to recall, and executive functions are more easily performed.

As of 2026, your channels for obtaining pharmaceutical-grade dihexa are relatively scarce. Most web-based outlets for the stuff are dealing in research-grade drugs, which we must reiterate are not fit for human consumption. Dihexa is already unproven on the safety front: you don’t want to compound the inherent danger with a mess of hazardous impurities.

Outside of the internet, you can maybe get your doctor to write you a prescription, but even there your chances are slim. Dihexa acetate, the compounding form used to make dihexa, is currently named among the restricted peptides on the U.S. Food & Drug Administration’s 503a bulks list, indicating steep restrictions owing to significant safety risks.15 With many such drugs, a person is denied access unless they qualify for an exemption, which would require that a licensed clinician has deemed the treatment to be “necessary for the identified patient.”16 With dihexa, the obstacle then is proving that it would be a more medically necessary option than some other treatment, when it pales in terms of efficacy and safety research even when compared with other category 2 cognitive health peptides. Something like Selank or Semax could be a more easily justifiable prescription than dihexa.

Yet that may all change in the near future. In February 2027, dihexa is slated to be among a handful of current category 2 peptides that will undergo FDA review for recategorization onto category 1.1 Should it pass evaluation, dihexa will join a list occupied by such substances as sermorelin and GLP-1 receptor agonists, hence expanding its prescription availability. We’ll be monitoring its research status in the meantime and will update this guide in accordance with developments in the space.